Immuneering Corporation (IMRX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Why Is Immuneering Stock Trading Higher On Tuesday?
On Tuesday, Immuneering Corporation IMRX revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms.
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
Why is Immuneering (IMRX) Stock Up 24% Today?
Various names in the biotech sector are seeing big moves in today's session, as investors are clearly interested in rotation into a number of higher-growth small-cap stocks. Immuneering (NASDAQ: IMRX ) is certainly one such company generating outsized interest today.
